menu
    • menu
    [{"orgOrder":0,"company":"Neopharm","sponsor":"Amarin","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Neopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neopharm \/ Amarin","highestDevelopmentStatusID":"15","companyTruncated":"Neopharm \/ Amarin"},{"orgOrder":0,"company":"Neopharm","sponsor":"Esperion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Bempedoic Acid","moa":"||ACL\/NPC1L1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Neopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Neopharm \/ Neopharm","highestDevelopmentStatusID":"15","companyTruncated":"Neopharm \/ Neopharm"}]

    Find Clinical Drug Pipeline Developments & Deals by Neopharm

    Menu

    Neopharm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neopharm

                            Israel arrow
                            BIO Asia-Taiwan
                            Not Confirmed

                            Neopharm

                            Israel arrow
                            BIO Asia-Taiwan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bempedoic Acid,Ezetimibe

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Recipient : Esperion Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Esperion Partners with Neopharm to Commercialize NEXLETOL and NEXLIZET in Israel

                            Details : Neopharm Israel gains exclusive rights to commercialize Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) in Israel for cardiovascular disease.

                            Product Name : Nexlizet

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 12, 2024

                            Lead Product(s) : Bempedoic Acid,Ezetimibe

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Esperion Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neopharm

                            Israel arrow
                            BIO Asia-Taiwan
                            Not Confirmed

                            Neopharm

                            Israel arrow
                            BIO Asia-Taiwan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Amarin

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Amarin and Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel

                            Details : Under the agreement, Amarin has appointed Neopharm as its sole and exclusive distributor of Vazkepa (icosapent ethyl) approved to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglyce...

                            Product Name : Vazkepa

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 08, 2023

                            Lead Product(s) : Icosapent Ethyl

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Amarin

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth